| 发明名称 | Antibody polypeptides that antagonize CD40L | ||
| 摘要 | Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen. | ||
| 申请公布号 | US9228018(B2) | 申请公布日期 | 2016.01.05 |
| 申请号 | US201414510474 | 申请日期 | 2014.10.09 |
| 申请人 | BRISTOL-MYERS SQUIBB COMPANY;DOMANTIS LIMITED | 发明人 | Nadler Steven G.;Tamura James K.;Price Laura;Rehfuss Robert P.;Suchard Suzanne J.;Suri Anish;Bryson James William;Yamniuk Aaron;Grant Steven;Ignatovich Olga;Drew Philip |
| 分类号 | A61K39/395;C07K16/28;A61K45/06;C07K16/46;C07K16/18;A61K39/00;A61K38/00 | 主分类号 | A61K39/395 |
| 代理机构 | Drinker Biddle & Reath LLP | 代理人 | Drinker Biddle & Reath LLP |
| 主权项 | 1. An isolated antibody polypeptide comprising a first variable domain that specifically binds human CD40L comprising the amino acid sequence of SEQ ID NO:1, wherein the amino acid sequence of the first variable domain is at least 95% identical to the amino acid sequence of BMS2h-572-633 (SEQ ID NO: 274). | ||
| 地址 | Princeton NJ US | ||